# GLP-1 Prescribing After a Heart Attack or Stroke: Czech Registry Data | This GLP Czech registry data on GLP-1 prescribing after heart attack and stroke in type 2 diabetes: about 2 percent uptake, lower MACE in matched users, and a mortality figure that points to healthy-user bias. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # GLP-1 Prescribing After a Heart Attack or Stroke: Czech Registry Data Czech national registry data covered heart attack and stroke survivors with type 2 diabetes from 2015 to 2024. About 2 percent were started on a GLP-1 within a year, despite a guideline recommending it. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Eligible survivors started on a GLP-1 within a year · ≈2% started · Each block is one in fifty. Guidelines recommend the drug for all of them. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Czech national registry data covered more than 300,000 heart attack and stroke survivors from 2015 to 2024. - Among those with type 2 diabetes, about 2% were started on a GLP-1 within a year of the event. - In matched cohorts, users had lower MACE: HR 0.70, 95% CI 0.52 to 0.93 after heart attack; 0.71, 0.54 to 0.94 after stroke. - All-cause death was HR 0.61 and 0.59 — as large as the cardiovascular effect, which is a warning sign rather than a bonus. - The treated arms were 401 and 385 people. Guidelines recommend these drugs after a heart attack or stroke in people with type 2 diabetes. A national registry can check whether that happens. It mostly does not. ## The number that does not need a causal claim Czech registry data from 2015 to 2024 identified 126,845 people surviving a first nonfatal heart attack, of whom 28,206 had confirmed type 2 diabetes, and 177,115 surviving an ischemic stroke, of whom 73,750 had it. [\[1\]](https://thisglp.com/research/glp1-uptake-after-heart-attack-stroke#ref-1) Roughly 2% of those survivors were started on a GLP-1 within twelve months. Use was lowest among women and older adults. That finding stands whatever you conclude about effectiveness. A recommended therapy reached one eligible patient in fifty. Nothing about study design changes it, and it is a different kind of gap from [the access limits sellers publish](https://thisglp.com/research/who-publishes-the-states-they-serve). ## What the matched comparison found Users were propensity-matched to non-users. After heart attack, the matched cohort was 2,271 people, 401 of them on a GLP-1, followed a median of 35 months. Major adverse cardiovascular events came in at HR 0.70, 95% CI 0.52 to 0.93. All-cause death was HR 0.61, 95% CI 0.47 to 0.80. Cardiovascular death was HR 0.54, 95% CI 0.36 to 0.80. After stroke, the matched cohort was 2,235 people, 385 on a GLP-1, median follow-up 27 months. MACE was HR 0.71, 95% CI 0.54 to 0.94. All-cause death HR 0.59, 95% CI 0.46 to 0.76. Cardiovascular death HR 0.55, 95% CI 0.37 to 0.81. Look at the all-cause number A drug that prevents heart attacks should move cardiovascular death more than it moves death from every cause combined. Here the all-cause figures are as large as the cardiovascular ones. That pattern is the fingerprint of healthy-user bias: the people who got started on a new drug in the year after a major event were the ones well enough, insured enough and engaged enough to be started on it. Matching cannot remove that, because being the sort of patient who gets offered a new therapy is not a variable anybody records. ## How much to believe The direction is almost certainly right. Randomized trials already established that these drugs reduce cardiovascular events in people with diabetes and existing disease, and [those trials are the reason to believe it](https://thisglp.com/research/semaglutide-cochrane-review). This registry is consistent with them. The magnitude is another matter. Four hundred treated patients, matched out of tens of thousands, with a mortality benefit that spills past the mechanism, is not a number to quote as an effect size. It is the same caution that applies to [any matched-records analysis](https://thisglp.com/research/semaglutide-fractures-diabetes-only), and it applies harder here because the treated group is small. ## Why a two percent figure matters here This site sells nothing to people recovering from a heart attack, and none of the clinical findings above transfer to a weight-loss purchase. The transferable part is about supply and attention. In a country with universal coverage and a recommending guideline, 98% of eligible patients did not get the drug — while a large commercial market sells the same molecules to people at far lower risk. That is not hypocrisy on anyone’s part and it is worth noticing. The gap between who a drug is proven to help and who actually buys it is the widest fact in this market, and [it is invisible from inside a trial](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care). What sellers record about who they ship to is thin, [measurably so](https://thisglp.com/tools/what-sellers-publish). ## Frequently asked Why did so few eligible patients get the drug? The study reports the shortfall rather than its causes, noting use was lowest among women and older adults. Cost, prescribing habit, specialty boundaries and competing priorities after a major event are all plausible and none is measured here. Does this prove the drug prevents death? No. All-cause mortality fell as much as cardiovascular events did, which is the pattern you expect when treated patients were healthier to begin with. Randomized trials, not this registry, are the reason to believe the cardiovascular benefit. How large was the treated group? 401 people in the heart attack cohort and 385 in the stroke cohort, matched from populations of 28,206 and 73,750 with diabetes. Does this apply to buying for weight loss? Not clinically. These were people with type 2 diabetes recovering from a major cardiovascular event. The transferable point is about access rather than effect. ## Sources 1. \[1\] Sedova P, et al. (2026). GLP-1 Receptor Agonists for Secondary Prevention After Myocardial Infarction and Stroke in Type 2 Diabetes: Nationwide Real-World Evidence European Journal of Preventive Cardiology. [PMID 41499432](https://pubmed.ncbi.nlm.nih.gov/41499432/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)